Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Protagonist Therapeutics (PTGX) Debt to Equity (2018 - 2023)

Historic Debt to Equity for Protagonist Therapeutics (PTGX) over the last 6 years, with Q2 2023 value amounting to $0.0.

  • Protagonist Therapeutics' Debt to Equity fell 8860.9% to $0.0 in Q2 2023 from the same period last year, while for Jun 2023 it was $0.0, marking a year-over-year decrease of 8860.9%. This contributed to the annual value of $0.0 for FY2022, which is 8931.99% down from last year.
  • Latest data reveals that Protagonist Therapeutics reported Debt to Equity of $0.0 as of Q2 2023, which was down 8860.9% from $0.0 recorded in Q1 2023.
  • Protagonist Therapeutics' 5-year Debt to Equity high stood at $0.03 for Q2 2021, and its period low was $0.0 during Q2 2023.
  • Over the past 5 years, Protagonist Therapeutics' median Debt to Equity value was $0.01 (recorded in 2019), while the average stood at $0.01.
  • Per our database at Business Quant, Protagonist Therapeutics' Debt to Equity skyrocketed by 43237.27% in 2021 and then plummeted by 9906.36% in 2022.
  • Protagonist Therapeutics' Debt to Equity (Quarter) stood at $0.02 in 2019, then plummeted by 38.09% to $0.01 in 2020, then plummeted by 69.33% to $0.0 in 2021, then tumbled by 89.32% to $0.0 in 2022, then plummeted by 89.37% to $0.0 in 2023.
  • Its Debt to Equity stands at $0.0 for Q2 2023, versus $0.0 for Q1 2023 and $0.0 for Q4 2022.